Literature DB >> 27986382

Dacryocystorhinostomy for Acquired Nasolacrimal Duct Stenosis in the Elderly (≥80 Years of Age).

Andrea A Tooley1, Kyle N Klingler2, George B Bartley1, James A Garrity1, John J Woog1, David Hodge3, Elizabeth A Bradley4.   

Abstract

PURPOSE: The incidence of acquired nasolacrimal duct obstruction (NLDO) increases with age. Dacryocystorhinostomy, the definitive treatment for NLDO, has a high success rate (80%-100%) with a low complication rate (1%-6%), but surgical outcomes have not been reported previously specifically for an elderly population, in which there may be increased risk for intraoperative and postoperative complications. The purpose of this study was to examine surgical outcomes and complication rates of dacryocystorhinostomy in an elderly population.
DESIGN: Retrospective cohort study. PARTICIPANTS: Patients 80 years of age or older undergoing external dacryocystorhinostomy at the Mayo Clinic between January 1, 1990, and December 31, 2010, were compared with a matched control group of younger patients (40-79 years of age) undergoing external dacryocystorhinostomy by the same surgeons.
METHODS: We reviewed the medical charts for patients as described above. Data abstracted from patient medical records included symptomatic relief and complications such as tube protrusion, infection, persistent bleeding, and return to operating room. Statistical analysis included a 2-sample t test to compare continuous variables, chi-square testing for categorical comparisons, and the generalized estimating equation model to control for nonindependence. MAIN OUTCOME MEASURES: Primary end point was symptomatic improvement at last follow-up. Secondary end points included anatomic patency, adverse event rate, and return to operating room within 1 month of surgery.
RESULTS: Forty-two dacryocystorhinostomies (32 patients) were performed in the elderly group. The control group comprised 73 dacryocystorhinostomies in 63 patients. Resolution of symptom rate at last follow-up was 64% in the elderly group versus 86% in the younger cohort (P = 0.02). Although there was no difference between groups with respect to common postoperative complications, there was a higher rate of predefined serious complications in the elderly group (5 events vs. 1 event; P = 0.01). There was no difference between groups regarding need for additional eyelid surgery (P = 0.30).
CONCLUSIONS: Although most elderly patients experience symptom resolution after dacryocystorhinostomy, the rate of symptom resolution was lower than that of younger patients. The risk of routine complications was similar between the groups. The risk of serious complications was higher in the elderly group.
Copyright © 2016 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27986382     DOI: 10.1016/j.ophtha.2016.10.018

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  4 in total

1.  Comparison of Tranexamic acid, Remifentanil, and Hydralazine on the bleeding volume during Dacryocystorhinostomy surgery.

Authors:  Darioush Moradi Farsani; Hamidreza Shetabi; Aryan Rafiee Zadeh; Niloofar Saffari Rad
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2022-06-15

2.  Transcanalicular Diode Laser-assisted Dacryocystorhinostomy for the Treatment of Primary Acquired Nasolacrimal Duct Obstruction.

Authors:  Joel M Mor; Yongwei Guo; Konrad R Koch; Ludwig M Heindl
Journal:  J Vis Exp       Date:  2017-10-13       Impact factor: 1.355

3.  External dacryocystorhinostomy conventional surgery versus Pawar implant: A comparative study.

Authors:  Deepak Mishra; Prashant Bhushan; Bibhuti P Sinha; Gyan Bhaskar; Raksha Rao
Journal:  Indian J Ophthalmol       Date:  2019-07       Impact factor: 1.848

4.  Surgical outcomes of endoscopic dacryocystorhinostomy: analysis of age effect.

Authors:  Jae Yun Sung; Yeon Hee Lee; Kyoung Nam Kim; Tae Seen Kang; Sung Bok Lee
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.